公开(公告)号：US20240182477A1

公开(公告)日：2024-06-06

申请号：US18472147

申请日：2023-09-21

Applicant: AMGEN INC. ,  VIGIL NEUROSCIENCE, INC.

Inventor： Lara C. CZABANIUK ,  Timothy HOPPER ,  Jonathan B. HOUZE ,  Jane PANTELEEV ,  Gwenaella RESCOURIO ,  Vincent SANTORA ,  Haoxuan WANG ,  Ryan D. WHITE ,  Alice R. WONG ,  Yongwei WU ,  Maxence BOS ,  John MANCUSO ,  Ivan FRANZONI

IPC: C07D487/04 ,  A61P25/28 ,  C07D413/14 ,  C07D471/04 ,  C07D475/00

CPC classification number: C07D487/04 ,  A61P25/28 ,  C07D413/14 ,  C07D471/04 ,  C07D475/00

Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”).




This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

公开(公告)号：US20230295169A1

公开(公告)日：2023-09-21

申请号：US18072501

申请日：2022-11-30

Applicant: AMGEN INC. ,  Vigil Neuroscience, Inc.

Inventor： Lara C. CZABANIUK ,  Timothy HOPPER ,  Jonathan B. HOUZE ,  Jane PANTELEEV ,  Gwenaella RESCOURIO ,  Vincent SANTORA ,  Haoxuan WANG ,  Ryan D. WHITE ,  Alice R. WONG ,  Yongwei WU ,  Maxence BOS ,  John MANCUSO ,  Ivan FRANZONI

IPC: C07D487/04 ,  A61P25/28 ,  C07D413/14 ,  C07D471/04

CPC classification number: C07D487/04 ,  A61P25/28 ,  C07D413/14 ,  C07D471/04

Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”).




This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

公开(公告)号：US20210230189A1

公开(公告)日：2021-07-29

申请号：US16078152

申请日：2017-02-24

Applicant: AMGEN INC.

Inventor： Sean P. BROWN ,  David Karl BEDKE ,  Micheal R. DEGRAFFENREID ,  Jiasheng FU ,  Zhihong LI ,  Felix GONZALEZ LOPEZ TURISO ,  Ana GONZALEZ BUENROSTRO ,  Micheal W. GRIBBLE, JR. ,  Micheal G. JOHNSON ,  Todd J. KOHN ,  Kexue LI ,  Yunxiao LI ,  Mike Elias LIZARZABURU ,  Yosup REW ,  Joshua TAYGERLY ,  Yingcal WANG ,  Xuelei YAN ,  Ming YU ,  Jiang ZHU ,  Manuel ZANCANELLA ,  Xian Yun JIAO ,  Liusheng ZHU ,  Xianghong WANG ,  Julio C. MEDINA ,  Jason A. DUQUETTE ,  Jonathan B. HOUZE ,  Marc VIMOLRATANA ,  Marlo G. CARDOZO ,  Alan C. CHENG

IPC: C07D513/10 ,  C07D515/10 ,  C07D513/20

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

公开(公告)号：US20240190863A1

公开(公告)日：2024-06-13

申请号：US17923160

申请日：2021-05-04

Applicant: AMGEN INC. ,  VIGIL NEUROSCIENCE, INC.

Inventor： Lara C. CZABANIUK ,  Timothy HOPPER ,  Jonathan B. HOUZE ,  Gwenaella RESCOURIO ,  Vincent SANTORA ,  Haoxuan WANG ,  Ryan D. WHITE ,  Alice R. WONG ,  Yongwei WU

IPC: C07D471/04 ,  A61K31/519 ,  A61K31/5377 ,  C07D413/14 ,  C07D519/00

CPC classification number: C07D471/04 ,  A61K31/519 ,  A61K31/5377 ,  C07D413/14 ,  C07D519/00

Abstract: The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (1).

公开(公告)号：US20230144581A1

公开(公告)日：2023-05-11

申请号：US18072497

申请日：2022-11-30

Applicant: AMGEN INC. ,  Vigil Neuroscience, Inc.

Inventor： Lara C. CZABANIUK ,  Timothy HOPPER ,  Jonathan B. HOUZE ,  Gwenaella RESCOURIO ,  Vincent SANTORA ,  Haoxuan WANG ,  Ryan D. WHITE ,  Alice R. WONG ,  Yongwei WU

IPC: C07D471/04 ,  C07D413/14

CPC classification number: C07D471/04 ,  C07D413/14

Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”).




This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

公开(公告)号：US20240124446A1

公开(公告)日：2024-04-18

申请号：US18309281

申请日：2023-04-28

Applicant: AMGEN INC. ,  Vigil Neuroscience, Inc.

Inventor： Lara C. CZABANIUK ,  Timothy HOPPER ,  Jonathan B. HOUZE ,  Gwenaella RESCOURIO ,  Vincent SANTORA ,  Haoxuan WANG ,  Ryan D. WHITE ,  Alice R. WONG ,  Yongwei WU

IPC: C07D471/04 ,  C07D413/14

CPC classification number: C07D471/04 ,  C07D413/14

Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”).




This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

公开(公告)号：US20230052348A1

公开(公告)日：2023-02-16

申请号：US17501075

申请日：2021-10-14

Applicant: AMGEN INC.

Inventor： Sean P BROWN ,  David Karl BEDKE ,  Michael R. DEGRAFFENREID ,  Jiasheng FU ,  Zhinghong LI ,  Felix GONZALEZ LOPEZ DE TURISO ,  Ana GONZALEZ BUENROSTRO ,  Michael W. GRIBBLE JR. ,  Michael G. JOHNSON ,  Todd J. KOHN ,  Kexue LI ,  Yunxiao LI ,  Mike Elias LIZARZABURU ,  Yosup REW ,  Joshua TAYGERLY ,  Yingcai WANG ,  Xuelei YAN ,  Ming YU ,  Jiang ZHU ,  Manuel ZANCANELLA ,  Xian Yun JIAO ,  Liusheng ZHU ,  Xianghong WANG ,  Julio C. MEDINA ,  Jason A. DUQUETTE ,  Jonathan B. HOUZE ,  Marc VIMOLRATANA ,  Mario G. CARDOZO ,  Alan C. CHENG

IPC: C07D513/10 ,  C07D513/20 ,  C07D515/10

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

公开(公告)号：US20230002390A1

公开(公告)日：2023-01-05

申请号：US17302502

申请日：2021-05-04

Applicant: AMGEN INC. ,  Vigil Neuroscience, Inc.

Inventor： Lara C. CZABANIUK ,  Timothy HOPPER ,  Jonathan B. HOUZE ,  Jane PANTELEEV ,  Gwenaella RESCOURIO ,  Vincent SANTORA ,  Haoxuan WANG ,  Ryan D. WHITE ,  Alice R. WONG ,  Yongwei WU ,  Maxence BOS ,  John MANCUSO ,  Ivan FRANZONI

IPC: C07D487/04 ,  A61P25/28 ,  C07D471/04 ,  C07D413/14

Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.